Early showed no clear difference in adverse events: infection compared with standard initiation of kidney replacement therapy (KRT) (high certainty).
Early leads to higher adverse events: hypotension compared with standard initiation of kidney replacement therapy (KRT) (high certainty).
Early leads to higher adverse events: hypophosphataemia compared with standard initiation of kidney replacement therapy (KRT) (high certainty).
Early leads to higher adverse events: cardiac‐rhythm disorder compared with standard initiation of kidney replacement therapy (KRT) (high certainty).
The review found no eligible studies for this question.
Angiotensin‐converting enzyme inhibitors may leads to higher adverse events: number reporting an adverse event compared with placebo (low certainty).
It is very uncertain whether angiotensin receptor blockers changes adverse events (number reporting an adverse event) compared with placebo (very low certainty).